Fig. 5
From: Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer
Metastases to distal sites assessed by ex vivo luminescence imaging (n = 5–6 mice). Box plot of ex vivo average radiance measured in excised (A) livers, (B) brains, and (C) lungs for each treatment group. Center line, median value; box, the 25th to 75th percentiles; whisker marks, the 5th and 95th percentiles. *P < 0.05, **P < 0.01, ***P < 0.001 by nonparametric Kruskal Wallis test. FUL, fulvestrant; LAS, lasofoxifene; PAL, palbociclib; Veh, vehicle